Riverbridge Partners LLC Sells 54,889 Shares of Repligen Corporation $RGEN

Riverbridge Partners LLC lessened its position in shares of Repligen Corporation (NASDAQ:RGEN) by 17.5% in the first quarter, HoldingsChannel.com reports. The firm owned 258,476 shares of the biotechnology company’s stock after selling 54,889 shares during the quarter. Riverbridge Partners LLC’s holdings in Repligen were worth $30,454,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. United Capital Financial Advisors LLC bought a new position in Repligen during the 3rd quarter worth approximately $368,387,000. Opti Capital Management LP bought a new stake in shares of Repligen in the 4th quarter valued at $2,399,209,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Repligen during the fourth quarter worth $199,176,000. Price T Rowe Associates Inc. MD increased its position in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the period. Finally, RTW Investments LP bought a new position in Repligen during the fourth quarter worth $174,347,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Jefferies Financial Group restated a “hold” rating and issued a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. HSBC dropped their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Canaccord Genuity Group decreased their target price on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Stock Down 0.2%

Shares of NASDAQ RGEN opened at $126.37 on Wednesday. The firm has a market cap of $7.13 billion, a PE ratio of 140.41, a P/E/G ratio of 2.44 and a beta of 1.09. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The company’s fifty day simple moving average is $121.94 and its 200 day simple moving average is $135.79. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.